Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207231 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 837
- Enrollment target
NCT02207231: Completed Phase 3 study, sponsored by Janssen Research & Development.
NCT02207231 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 837 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207231, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 837 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
Primary Outcome
The IGA documents the investigator's assessment of the participants' psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Interventions
- DRUG Adalimumab
- DRUG Placebo for guselkumab
- DRUG Placebo for adalimumab
- DRUG Guselkumab 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 837 participants |
| Start Date | 2014-11-26 |
| Est. Completion | 2020-06-17 |
| Phase | Phase 3 |
What the finished NCT02207231 record still lists
NCT02207231 is an interventional study that assigns participants to a tested intervention. The registered 837 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Adalimumab is the first listed.
NCT02207231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02207231 about?
NCT02207231 is a clinical study titled "A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis". The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
What is the current status of trial NCT02207231?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 837 participants. The study started on 2014-11-26. Estimated completion is 2020-06-17.
What interventions are being tested in trial NCT02207231?
The interventions under investigation include: Adalimumab (DRUG), Placebo for guselkumab (DRUG), Placebo for adalimumab (DRUG), Guselkumab 100 mg (DRUG).
Who is sponsoring clinical trial NCT02207231?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02207231's enrollment target sits among peer trials
837 395th of 2000 higher than 1,605 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422550 · 837 participants
Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment
- NCT02118467 · 836 participants · Phase 4
Vasoactive Drugs in Intensive Care Unit
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI